Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT01137747 Completed - Leukemia Clinical Trials

Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia

AML ALL
Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study is to test escalating doses of carfilzomib in patients with relapsed acute myeloid and acute lymphoblastic leukemia.

NCT ID: NCT01134575 Completed - Clinical trials for Acute Lymphoblastic Leukemia

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: June 4, 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.

NCT ID: NCT01133743 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

Start date: May 2010
Phase: Phase 2
Study type: Interventional

This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR or to a maximum of 18 cycles, each cycle of 28 days duration. Primary endpoint is response.

NCT ID: NCT01132573 Completed - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/biphenotypic leukemia. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving entinostat with clofarabine may kill more cancer cells.

NCT ID: NCT01129193 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Start date: May 4, 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AR-42 in treating patients with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, or lymphoma.

NCT ID: NCT01123356 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).

NCT ID: NCT01121133 Completed - Solid Tumors Clinical Trials

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.

NCT ID: NCT01120457 Completed - Clinical trials for Chronic Lymphocytic Leukemia

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the drug alone in relapsed/refractory AML

NCT ID: NCT01119586 Completed - Leukemia Clinical Trials

Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia

Start date: February 2013
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in DNA samples from patients with newly diagnosed high-risk acute lymphoblastic leukemia.

NCT ID: NCT01118234 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of Rituximab maintenance therapy to prolong progression free survival in patients with chronic lymphocytic leukemia, who responded to a Rituximab induction therapy.